Clinical trial • Phase I • Infectious Disease
CD5 CAR-NK cells for Refractory invasive mold disease | Fungal infection
Phase I trial of CD5 CAR-NK cells for Refractory invasive mold disease | Fungal infection. 10 participants.
Overview
- Trial Therapeutic Area
- Infectious Disease
- Trial Disease
- Refractory invasive mold disease | Fungal infection
- Trial Stage
- Phase I
- Drug Modality
- Cell therapy
Key dates
- Initial CTIS Submission Date
- 16-01-2026
- First CTIS Authorization Date
- 04-05-2026
Trial design
Phase I trial across 1 site in Spain.
- Target Sample Size
- 10
- Trial Duration For Participant
- 1096
Eligibility
Recruits 10 Vulnerable population selected; no details on consent or assent handling provided..
- Vulnerable Population
- Vulnerable population selected; no details on consent or assent handling provided.
Recruitment
- Planned Sample Size
- 10
- Recruitment Window Months
- 36
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 10
Spain
- Earliest CTIS Part Ii Submission Date
- 02-04-2026
- Latest Decision Or Authorization Date
- 04-05-2026
- Processing Time Days
- 32
- Number Of Sites
- 1
- Number Of Participants
- 10
Sites
- Site Name
- Hospital Clinic De Barcelona
- Department Name
- Infectious Diseases
- Principal Investigator Name
- Carolina Garcia
- Principal Investigator Email
- CGARCIAV@clinic.cat
- Contact Person Name
- Carolina Garcia
- Contact Person Email
- CGARCIAV@clinic.cat
- Number Of Participants
- 10
Sponsor
Primary sponsor
- Full Name
- Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
- Organisation Type
- Laboratory/Research/Testing facility
- Country Of Registered Address
- Spain
Investigational products
- Investigational Product Name
- CD5CAR-NK
- Active Substance
- CD5 CAR-NK cells
- Modality
- Cell therapy
Related trials
Other published trials that may interest you.
- Conditioned medium from a co-culture of M2-macrophages and fat-derived mesenchymal cells for Acute respiratory distress syndrome (ARDS) | SARS-CoV-2 infection | Influenza A infection | Influenza B infection | Respiratory syncytial virus (RSV) infection
- ACICLOVIR for Recurrent herpes labialis | Herpes simplex labialis
- AMIKACIN SULFATE for Sepsis | Neutropenia
- LENACAPAVIR, ISLATRAVIR for HIV-1 infection
- piperacillin sodium, tazobactam sodium for Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae severe infection